Intuitive Surgical, Inc. (ISRG) Stock Analysis
Is ISRG a good investment?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 72.0/100 as of October 02, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Profitability fortress: Gross margin 66.7% (+50.7% vs. peers), operating margin 33.6% (+142.9% vs. peers), net margin 28.4% (+439.4% vs. peers) — ISRG's moat is quantifiably superior to every peer in the 21-company sector group. Main concern: Valuation stretched with minimal margin of safety: P/E of 45.99x against next-year EPS growth of 11.9% implies earnings yield of ~2.17%; DCF fair value of $270-$320 implies 20-33% overvaluation on standalone basis; stock has rallied ~$40 (+10.8%) in 14 days with zero change in analyst consensus ($474.96 unchanged), fundamentals, or business trajectory — pure multiple expansion from 41.3x to 46x.
Investment Summary
Intuitive Surgical (ISRG) at $401.24 is a world-class business trapped in an overvalued stock. The company posts gross margins of 66.7% (vs. 44.25% industry average), operating margins of 33.6% (vs. 13.83% peers), net margins of 28.4% (vs. 5.27% peers), and $3.22B in annual free cash flow with zero debt and $5.2B cash on the balance sheet — metrics that place it in a category of its own within the 21-company Medical Instruments peer group. However, the P/E of 45.99x against next-year EPS growth of only 11.9% is the central problem: investors are paying ~46x for ~12% near-term earnings growth, yielding an implied earnings yield of just 2.17%. The PEG of 3.06x, while 21.7% below the industry average of 3.90x, remains elevated in absolute terms. News sentiment is strongly positive at 94.2/100, with AI/da Vinci 5 integration, ASC expansion, and robotics tailwinds all constructive for the long-term thesis. The 5-year forward EPS growth of 15.1% supports a long-term bull case, but the current price demands perfection. At $401.24, implied upside to analyst consensus of $474.96 is 18.4% — attractive in isolation, but the stock has rallied ~10% in two weeks with zero fundamental change. Wait for the $368-$383 entry zone.
Key Strengths
- Profitability fortress: Gross margin 66.7% (+50.7% vs. peers), operating margin 33.6% (+142.9% vs. peers), net margin 28.4% (+439.4% vs. peers) — ISRG's moat is quantifiably superior to every peer in the 21-company sector group
- Zero-debt balance sheet with $5.2B cash and $3.22B annual FCF: D/E of 0.0 vs. industry 0.536 eliminates financial risk entirely and provides unmatched strategic optionality; AI/da Vinci 5 integration and ASC expansion are funded internally with no dilution risk
- Relative PEG discount despite premium absolute valuation: PEG of 3.06x is 21.7% BELOW industry average of 3.90x, and 5-year forward EPS growth of 15.05% exceeds peers by 24.9% — ISRG's P/E premium of 28.8% over peers is mathematically justified by superior long-term compounding
Key Concerns
- Valuation stretched with minimal margin of safety: P/E of 45.99x against next-year EPS growth of 11.9% implies earnings yield of ~2.17%; DCF fair value of $270-$320 implies 20-33% overvaluation on standalone basis; stock has rallied ~$40 (+10.8%) in 14 days with zero change in analyst consensus ($474.96 unchanged), fundamentals, or business trajectory — pure multiple expansion from 41.3x to 46x
- Near-term growth deceleration creates asymmetric downside risk: EPS growth decelerating from historical 26.5% to projected 11.9% next year (a 55% reduction in earnings momentum); at 46x P/E, any guidance miss, procedure volume shortfall, or reimbursement headwind could trigger 15-25% multiple compression, as confirmed by the headline 'Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?' which documents the stock's demonstrated downside volatility
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ISRG's fundamentals are exceptional across every profitability and health metric. Gross margin: 66.7% vs. industry 44.25% (+22.4pp advantage). Operating margin: 33.6% vs. industry 13.83% (+19.8pp advantage). Net margin: 28.4% vs. industry 5.27% (+23.1pp advantage — a 439% premium). ROE: 17.43% vs. industry 6.90% (+152.5%), even while carrying $5.2B in dilutive cash. D/E ratio: effectively 0.0 vs. industry 0.536. FCF: $3.22B annually — genuine, high-quality cash generation. Growth is the one blemish: historical EPS growth of 26.5% is decelerating to a 5-year forward projection of 15.1% and a next-year estimate of only 11.9%, representing a ~55% deceleration in near-term earnings momentum. The P/E of 45.99x vs. a justified DCF-implied P/E of 28-35x (using 9% discount rate, 15.1% 5-year growth, 5% terminal rate) suggests intrinsic value of approximately $270-$320, or 20-33% below current price on a standalone basis. The relative valuation is more forgiving: PEG of 3.06x is 21.7% BELOW the industry average of 3.90x, and ISRG's 5-year EPS growth of 15.05% exceeds the industry average of 12.05% by 25%, justifying a PE premium. Revenue growth of 18.5% also leads peers by 55.8%. Bottom line: spectacular business at a price that requires flawless execution.
News Sentiment
Intuitive Surgical is making headlines for all the right long-term reasons — but the stock's price tag remains the story investors can't ignore. The maker of the iconic da Vinci surgical robot is doubling down on the future of medicine. The company is integrating artificial intelligence, advanced software, and data analytics directly into its next-generation da Vinci 5 platform, positioning itself at the intersection of two of the hottest themes in technology: robotics and AI. One headline — 'Move Over Tesla: Intuitive Surgical Shows Why Robotics Could Be Bigger Than Humanoid Robots' — captures why long-term bulls remain enthusiastic: specialized surgical robotics may represent a more immediate and defensible investment opportunity than the futuristic humanoid robot race. Separately, ISRG is actively developing advanced surgical instruments to extend its competitive moat, suggesting the innovation pipeline remains robust and that the company isn't resting on its da Vinci laurels. But the bullish narrative is tempered by valuation reality. One headline asks plainly: 'Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.' — a neutral challenge that captures the market's genuine debate between ISRG's extraordinary business quality and its 46x price-to-earnings multiple. Another compares ISRG directly to Abbott Laboratories as a healthcare investment choice, underscoring that investors seeking value have alternatives. Perhaps most telling: 'Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?' — a reminder that this exact stock, despite its world-class fundamentals, demonstrated severe downside volatility in 2025, and that premium multiples carry real risk when sentiment shifts.
Risk Assessment
PRIMARY RISK: Multiple compression. At P/E 45.99x with next-year EPS growth of 11.9%, the stock is priced for perfection. A reversion to a 38x P/E (still premium to the 35.72x industry average) would imply a stock price of ~$330 — roughly 18% downside from current levels. This compression could be triggered by any procedure volume miss, reimbursement policy changes, or macro-driven risk-off rotation out of high-multiple healthcare names. SECONDARY RISK: Growth deceleration confirmation. If next-year EPS comes in at or below the 11.9% projection (vs. the historical 26.5%), institutional holders may reassess the growth premium embedded in the 46x multiple. MITIGATION: The $5.2B cash hoard and zero debt provide a permanent floor — ISRG cannot go bankrupt and can buy back shares aggressively if price falls. The 21.7% PEG discount to peers limits relative underperformance risk vs. sector. Long-term AI/robotics tailwinds (da Vinci 5, ASC expansion) remain intact. STOP LOSS at $347: approximately 7.6% below entry midpoint of $375.50, just below major YTD recovery support and the prior week's trading range; gives the position room to breathe while capping downside to a manageable loss.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ISRG a halal stock?
No, Intuitive Surgical, Inc. (ISRG) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ISRG?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 72.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ISRG a good investment?
According to Plutrex AI, ISRG has a Buy rating (72.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ISRG?
US stocks like ISRG can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ISRG?
Plutrex AI identifies the main risks for ISRG by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.